12 citations,
August 2022 in “Stem cell reviews and reports” Increasing PBX1 reduces aging and cell death in hair follicle stem cells by boosting SIRT1 and lowering PARP1 activity.
3 citations,
April 2022 in “Research Square (Research Square)” PBX1 reduces aging and cell death in stem cells by boosting SIRT1 and lowering PARP1.
18 citations,
February 2022 in “Cell Death Discovery” The study demonstrates that ECM1-modified hair follicle-derived mesenchymal stem cells (ECM1-HF-MSCs) can effectively treat liver cirrhosis by inhibiting the TGF-β/Smad signaling pathway, which is crucial in liver fibrosis. Using a mouse model of liver cirrhosis induced by CCl4, the research shows that ECM1-HF-MSCs improve liver function and reduce liver injury more effectively than naïve HF-MSCs. These modified cells migrate to the liver, express hepatocyte-specific markers, and significantly inhibit hepatic stellate cell activation. The findings suggest that ECM1-HF-MSCs offer a promising therapeutic approach for liver cirrhosis through genetic modification.
69 citations,
April 2019 in “Biomedicines” PRP and HF-MSCs treatment improves hair growth, thickness, and density in androgenetic alopecia.
3 citations,
January 2021 in “Oxidative Medicine and Cellular Longevity” Nrf-2-modified stem cells from hair follicles significantly improve ulcerative colitis in rats.